Watanabe M, Fukamachi H, Uzumaki H, Kabaya K, Tsumura H, Ishikawa M, Matsuki S, Kusaka M
Pharmaceutical Research Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan.
Anal Biochem. 1991 May 15;195(1):38-44. doi: 10.1016/0003-2697(91)90291-z.
A new mutant protein of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was produced for the studies on receptors for human G-CSF. The mutant protein [(Tyr1, Tyr3]rhG-CSF), the biological activity of which was almost equal to that of rhG-CSF, was prepared by the replacement of threonine-1 and leucine-3 of rhG-CSF with tyrosine. The radioiodinated preparation of the mutant protein showed high specific radioactivity and retained full biological activity for at least 3 weeks. The binding capacity of the radioiodinated ligand was compared with that of [35S]rhG-CSF. Both radiolabeled ligands showed specific binding to murine bone marrow cells. Unlabeled rhG-CSF and human G-CSF purified from the culture supernatant of the human bladder carcinoma cell line 5637 equally competed for the binding of labeled rhG-CSFs in a dose-dependent manner, demonstrating that the sugar moiety of human G-CSF made no contribution to the binding of human G-CSF to target cells. In contrast, all other colony-stimulating factors and lymphokines examined did not affect the binding. Scatchard analysis of the specific binding of both labeled ligands revealed a single class of binding site with an apparent dissociation constant (Kd) of 20-30 pM and 100-200 maximal binding sites per cell. These data indicate that the radioiodinated preparation of the mutant protein binds the same specific receptor with the same affinity as [35S]rhG-CSF. The labeled mutant protein also showed specific binding to human circulating neutrophils.(ABSTRACT TRUNCATED AT 250 WORDS)
为了研究人粒细胞集落刺激因子(G-CSF)的受体,制备了一种重组人粒细胞集落刺激因子(rhG-CSF)的新突变蛋白。该突变蛋白[(Tyr1,Tyr3)rhG-CSF]是通过将rhG-CSF的苏氨酸-1和亮氨酸-3替换为酪氨酸而制备的,其生物学活性几乎与rhG-CSF相同。该突变蛋白的放射性碘标记制剂显示出高比放射性,并在至少3周内保持了全部生物学活性。将放射性碘标记配体的结合能力与[35S]rhG-CSF的结合能力进行了比较。两种放射性标记配体均显示与小鼠骨髓细胞有特异性结合。未标记的rhG-CSF和从人膀胱癌细胞系5637的培养上清液中纯化的人G-CSF以剂量依赖的方式同等程度地竞争标记的rhG-CSF的结合,表明人G-CSF的糖基部分对人G-CSF与靶细胞的结合没有贡献。相比之下,所检测的所有其他集落刺激因子和淋巴因子均不影响结合。对两种标记配体的特异性结合进行Scatchard分析,结果显示存在一类结合位点,其表观解离常数(Kd)为20 - 30 pM,每个细胞有100 - 200个最大结合位点。这些数据表明,突变蛋白的放射性碘标记制剂与[35S]rhG-CSF以相同的亲和力结合相同的特异性受体。标记的突变蛋白也显示与人类循环中性粒细胞有特异性结合。(摘要截短于250字)